Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.36 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | FDPS | P14324 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 5/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 4/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2236544 | 0.93 | TP53 (0.47) | TP53ACE2FDPSCA2OPRM1 | |
| SCHEMBL17319467 | 0.85 | TSHR (0.42) | TP53TSHRSMN1; SMN2CA2CA1 | |
| SCHEMBL2233250 | 0.85 | TSHR (0.42) | TP53TSHRSMN1; SMN2CA2CA1 | |
| SCHEMBL9622847 | 0.83 | TP53 (0.40) | TP53ACE2DNM1TSHRSMN1; SMN2 | |
| SCHEMBL8813015 | 0.81 | TP53 (0.39) | TP53ACE2DNM1TSHRSMN1; SMN2 | |
| SCHEMBL23181465 | 0.79 | TP53 (0.38) | TP53ACE2DNM1TSHRSMN1; SMN2 | |
| SCHEMBL5572373 | 0.79 | TP53 (0.47) | TP53ACE2FDPSCA2MAPK1 | |
| SCHEMBL5572371 | 0.79 | TP53 (0.47) | TP53ACE2FDPSCA2MAPK1 | |
| SCHEMBL27951226 | 0.79 | TP53 (0.42) | TP53ACE2CA2OPRM1CA1 | |
| SCHEMBL8812271 | 0.74 | TP53 (0.47) | TP53ACE2FDPSCA2OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8466324-B2 | Sulfone compound | SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) | 2013-06-18 | — | — | US | disclosed |
| US-8426208-B2 | Method and apparatus for determining radiation | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2013-04-23 | — | — | US | disclosed |
| US-20120295360-A1 | METHOD AND APPARATUS FOR DETERMINING RADIATION | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2012-11-22 | — | — | US | disclosed |
| US-8187887-B2 | Method and apparatus for determining radiation | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2012-05-29 | — | — | US | disclosed |
| US-20110257438-A1 | SULFONE COMPOUND | SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) | 2011-10-20 | — | — | US | disclosed |
| US-20110081724-A1 | METHOD AND APPARATUS FOR DETERMINING RADIATION | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2011-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257438-A1 | SULFONE COMPOUND | SULT1E1, SULT1A1, STS | TP53 4133/4885ACE2 755/4885DNM1 3164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.